ERBB2 and breast cancer: Samples from 1702 postmenopausal patients with ER+/HER2-negative early-stage BC treated with 5 years of ET from the two phase-III adjuvant studies ABCSG6 and ABCSG8 were collected to investigate the ability of EP to estimate early (<5 years) and late (>5 years) risk of relapse.